Multiple micronodular diseases of lung in gynecologic malignancies

Molecular pathology-integrated clinicopathological prognostic factors

“…

Malignant diseases are the main and leading cause of death in Taiwan, contributing to an urgent need of active care for patients with malignant diseases, regardless whether the earlyor late-stage of diseases are defined. [1][2][3] Cancer treatment can be simply grouped into two distinguished therapeutic approaches; one is the highly curative therapy applied either by surgery alone and/or radiation therapy with/without neoadjuvant therapy (NAT) or adjuvant therapy under multi-modality guidance; and the other is the palliative therapy or multidisciplinary decision-making with low possibility of curability, based on the characteristics and patterns of diseases at the initial diagnosis. [4][5][6][7][8][9] Except of some specific systemic diseases, patients with an in situ or organ-limited diseases have a better chance to be cured accompanied with a long-term survival after the initial primary curative treatment.

…”

“…12 Multidisciplinary team or multimodality treatment is encouraged for advanced-stage cancer patients. 2,3,8,9 Since to offer a better chance of survival in the advanced-stage cancer patients is always our goal or our dream, although it is far away from the real world, suggesting the presence of a large discrepancy or a big gap between NCCN recommendation and real-world clinical practice.…”